Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus doxorubicin versus doxorubicin alone as first-line treatment for advanced soft tissue sarcoma
ChiCTR2100049157Phase 2Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Apr 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of camrelizumab and doxorubicin in soft tissue sarcoma (STS) (2 arms), sponsored by Union Hospital. Primary endpoint: Progression-free survival. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
camrelizumabdoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2100049157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049157.